These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 23643389)
21. Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer. Hao Y; He B; Wu L; Li Y; Wang C; Wang T; Sun L; Zhang Y; Zhan Y; Zhao Y; Markowitz S; Veigl M; Conlon RA; Wang Z Nat Commun; 2022 Apr; 13(1):1974. PubMed ID: 35418124 [TBL] [Abstract][Full Text] [Related]
22. Biophysical aspect of phosphatidylinositol 3-kinase and role of oncogenic mutants (E542K & E545K). Kalsi N; Gopalakrishnan C; Rajendran V; Purohit R J Biomol Struct Dyn; 2016 Dec; 34(12):2711-2721. PubMed ID: 26646651 [TBL] [Abstract][Full Text] [Related]
23. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. Hon WC; Berndt A; Williams RL Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714 [TBL] [Abstract][Full Text] [Related]
25. Rare cancer-specific mutations in PIK3CA show gain of function. Gymnopoulos M; Elsliger MA; Vogt PK Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5569-74. PubMed ID: 17376864 [TBL] [Abstract][Full Text] [Related]
26. Connecting with an old partner in a new way. Burke JE; Williams RL Cancer Cell; 2013 May; 23(5):559-61. PubMed ID: 23680139 [TBL] [Abstract][Full Text] [Related]
27. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460 [TBL] [Abstract][Full Text] [Related]
28. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061 [TBL] [Abstract][Full Text] [Related]
29. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702 [TBL] [Abstract][Full Text] [Related]
30. Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Chaussade C; Cho K; Mawson C; Rewcastle GW; Shepherd PR Biochem Biophys Res Commun; 2009 Apr; 381(4):577-81. PubMed ID: 19233141 [TBL] [Abstract][Full Text] [Related]
31. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α. Echeverria I; Liu Y; Gabelli SB; Amzel LM FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737 [TBL] [Abstract][Full Text] [Related]
32. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Rudd ML; Price JC; Fogoros S; Godwin AK; Sgroi DC; Merino MJ; Bell DW Clin Cancer Res; 2011 Mar; 17(6):1331-40. PubMed ID: 21266528 [TBL] [Abstract][Full Text] [Related]
33. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485 [TBL] [Abstract][Full Text] [Related]
34. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Mandelker D; Gabelli SB; Schmidt-Kittler O; Zhu J; Cheong I; Huang CH; Kinzler KW; Vogelstein B; Amzel LM Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16996-7001. PubMed ID: 19805105 [TBL] [Abstract][Full Text] [Related]
35. Oncogenic mutations of PIK3CA in human cancers. Samuels Y; Velculescu VE Cell Cycle; 2004 Oct; 3(10):1221-4. PubMed ID: 15467468 [TBL] [Abstract][Full Text] [Related]
36. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Adams JR; Xu K; Liu JC; Agamez NM; Loch AJ; Wong RG; Wang W; Wright KL; Lane TF; Zacksenhaus E; Egan SE Cancer Res; 2011 Apr; 71(7):2706-17. PubMed ID: 21324922 [TBL] [Abstract][Full Text] [Related]
37. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450 [TBL] [Abstract][Full Text] [Related]
38. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer. Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157 [TBL] [Abstract][Full Text] [Related]
39. PAQR3 modulates insulin signaling by shunting phosphoinositide 3-kinase p110α to the Golgi apparatus. Wang X; Wang L; Zhu L; Pan Y; Xiao F; Liu W; Wang Z; Guo F; Liu Y; Thomas WG; Chen Y Diabetes; 2013 Feb; 62(2):444-56. PubMed ID: 23086038 [TBL] [Abstract][Full Text] [Related]
40. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. Wu H; Shekar SC; Flinn RJ; El-Sibai M; Jaiswal BS; Sen KI; Janakiraman V; Seshagiri S; Gerfen GJ; Girvin ME; Backer JM Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20258-63. PubMed ID: 19915146 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]